Carcinoid tumour of the gastrointestinal tract – Diagnostics – Overview of Information and Clinical Research

Diagnosing carcinoid tumors of the gastrointestinal tract often begins with understanding which patients need testing and when to look for these rare, slow-growing cancers that can hide for years without clear symptoms.

Introduction: Who Should Seek Diagnostic Testing

Gastrointestinal carcinoid tumors present a unique challenge in medicine because they often remain silent for many years. Many people carry these tumors without ever knowing, as they tend to grow very slowly and may not produce any noticeable signs early on^[1]. This means that knowing when to seek diagnostic testing is not always straightforward.

People should consider diagnostic evaluation when they experience persistent digestive problems that don’t improve with standard treatment. If you have ongoing abdominal pain, unexplained changes in bowel habits such as chronic diarrhea, or recurring nausea and vomiting without a clear cause, these symptoms warrant medical attention^[2]. However, not all carcinoid tumors announce themselves through symptoms. Many are discovered accidentally during procedures performed for entirely different reasons, such as an appendectomy or colonoscopy for routine screening^[3].

Individuals with a family history of certain genetic conditions should be particularly vigilant. If multiple endocrine neoplasia type 1 (MEN1)—a condition where several hormone-producing glands develop tumors—or neurofibromatosis type 1 (NF1)—a disorder causing tumors to grow on nerve tissue—runs in your family, you face higher risk^[3]. Similarly, people with stomach conditions that reduce acid production, such as atrophic gastritis (chronic inflammation leading to loss of stomach glands), pernicious anemia (vitamin B12 deficiency due to stomach issues), or Zollinger-Ellison syndrome (tumors causing excessive stomach acid), should discuss screening with their healthcare provider^[3].

A special set of symptoms called carcinoid syndrome should prompt immediate medical investigation. This syndrome occurs when tumors release excessive amounts of hormones into the bloodstream, typically after spreading to the liver. The hallmark signs include repeated episodes of facial flushing (sudden redness and warmth in the face and neck), watery diarrhea that occurs multiple times daily, wheezing or difficulty breathing, and unexplained weight gain particularly around the midsection and upper back^[2]. Some patients also develop skin marks resembling stretch marks that appear pink or purple. However, it’s important to know that carcinoid syndrome is relatively rare, occurring in only about one in five patients with carcinoid tumors, and when it does appear, the vast majority already have liver involvement^[6].

⚠️ Important

Carcinoid tumors are frequently discovered by chance during surgery or testing for other health issues. If your doctor finds a carcinoid tumor during an unrelated procedure, this is actually quite common and occurs in about 40% of cases. Don’t be alarmed—many of these incidentally discovered tumors are small and have an excellent outlook when treated promptly.

Classic Diagnostic Methods

When doctors suspect a carcinoid tumor, they use a combination of approaches to confirm the diagnosis and understand the tumor’s characteristics. The diagnostic journey typically begins with less invasive tests and progresses to more detailed examinations if needed.

Blood and Urine Testing

The first diagnostic steps often involve analyzing substances in your blood and urine. Carcinoid tumors that produce hormones leave chemical fingerprints that can be detected through laboratory testing. One of the most important tests measures a substance called 5-hydroxyindoleacetic acid (5-HIAA) in a 24-hour urine collection^[11]. This chemical is created when your body breaks down serotonin, a hormone that many carcinoid tumors produce in excess. Elevated levels strongly suggest the presence of a functioning carcinoid tumor, though the height of the level doesn’t always match how severe your symptoms are^[6].

Blood tests complement urine analysis by measuring levels of hormones and other substances released by tumors. A blood test for chromogranin A serves as another important marker, as this protein is often elevated in patients with neuroendocrine tumors including carcinoids^[12]^[19]. When carcinoid syndrome is present, blood may show high levels of various hormones that the tumor secretes. Importantly, about one-third of patients with proven carcinoid tumors will show elevated 5-HIAA even without having full-blown carcinoid syndrome, and occasionally these elevations occur even when tumors haven’t spread to the liver^[6].

Imaging Studies

Seeing the tumor itself requires imaging technology. Doctors employ multiple imaging techniques because each offers different advantages in locating and characterizing carcinoid tumors throughout the digestive tract^[3].

Computed tomography (CT) scans use X-rays and computer processing to create detailed cross-sectional images of your abdomen. Since most carcinoid tumors develop in the gastrointestinal tract, a CT scan of the abdomen is often the starting point for imaging^[11]. These scans can identify the tumor’s location, measure its size, and detect whether it has spread to nearby lymph nodes or the liver.

Magnetic resonance imaging (MRI) employs powerful magnets and radio waves instead of radiation to generate extremely detailed pictures of soft tissues. MRI can be particularly helpful in certain situations where soft tissue detail is crucial or when evaluating the liver for metastatic spread^[11].

A specialized nuclear medicine scan called somatostatin receptor scintigraphy (often referred to as an OctreoScan) has become invaluable for carcinoid diagnosis. This test involves injecting a radioactive substance that binds to receptors commonly found on carcinoid tumor cells. A special camera then detects the radioactivity, revealing tumor locations throughout the body^[11]. This technique is particularly powerful because it can find small tumors and metastases that other imaging might miss, essentially lighting up wherever carcinoid cells are present.

Positron emission tomography (PET) scans represent another nuclear medicine approach that can help pinpoint active tumor tissue by detecting areas of increased metabolic activity^[11].

Endoscopic Procedures and Tissue Sampling

Directly visualizing the inside of the digestive tract provides irreplaceable information. Endoscopic procedures use flexible tubes equipped with tiny cameras to examine the gastrointestinal lining from the inside.

Upper endoscopy (also called esophagogastroduodenoscopy or EGD) involves passing a thin, flexible tube with a camera through your mouth and down your throat to examine your esophagus, stomach, and the first part of your small intestine. This allows doctors to see tumors in these areas and take tissue samples^[11].

Colonoscopy examines the large intestine by inserting a scope through the rectum. This procedure is essential for diagnosing rectal carcinoid tumors and can detect tumors throughout the colon^[11]. A shorter version called sigmoidoscopy examines just the lower portion of the colon and rectum.

For the middle portions of the small intestine that traditional endoscopes cannot reach, doctors may use capsule endoscopy. You swallow a pill-sized camera that takes thousands of pictures as it naturally passes through your digestive system^[11]. A newer technique called endoscopic ultrasound combines endoscopy with ultrasound imaging to get detailed views of the intestinal wall and surrounding tissues^[11].

The definitive confirmation of carcinoid tumor diagnosis requires obtaining actual tumor tissue for examination under a microscope—a process called biopsy. During endoscopic procedures, doctors can use small instruments to remove tissue samples. In some cases, a needle biopsy may be performed, where a needle is inserted through the skin to collect cells from a suspected tumor^[11]. Laboratory specialists then examine these samples to confirm whether carcinoid cells are present, determine how aggressive they appear, and identify what types of cells make up the tumor^[11].

Additional Specialized Tests

Certain situations call for more specialized diagnostic approaches. Bronchoscopy—passing a scope down the throat and into the lungs—helps find lung carcinoid tumors when imaging suggests they might be present^[11].

Some centers use endoscopic retrograde cholangiopancreatography (ERCP), which combines endoscopy with X-ray imaging to examine the bile ducts and pancreatic ducts. This can be useful when carcinoid tumors affect these areas or when trying to distinguish carcinoid from other types of tumors.

Physical examination remains important despite advanced technology. A digital rectal exam, where the doctor inserts a gloved finger into the rectum to feel for abnormalities, can detect some rectal carcinoid tumors during routine examinations.

Diagnostics for Clinical Trial Qualification

When patients consider participating in clinical trials testing new treatments for carcinoid tumors, they undergo additional diagnostic evaluations beyond standard clinical practice. Clinical trials follow strict protocols that require specific evidence to confirm eligibility and establish baseline measurements against which treatment effects can be measured.

Most clinical trials require documented proof of carcinoid tumor through biopsy confirmation. The tissue samples must show characteristic features under microscopic examination, and often researchers request additional testing on the biopsy material. They may check for specific markers that identify cells as neuroendocrine in origin, or perform genetic testing to understand the tumor’s molecular characteristics^[16].

Imaging studies serve dual purposes in trial enrollment. First, they establish the extent of disease spread—whether tumors remain localized or have metastasized to distant organs. Many trials specifically recruit patients with metastatic disease, while others focus on earlier stages. Second, imaging provides baseline measurements of tumor size that researchers will use to evaluate whether experimental treatments shrink tumors or slow their growth. Trials typically require recent scans, often performed within four to six weeks before enrollment, using standardized techniques to ensure measurements can be accurately compared over time.

Biochemical marker measurements form another crucial component of trial eligibility criteria. Researchers commonly require baseline measurements of chromogranin A and 24-hour urinary 5-HIAA before treatment begins^[12]. For trials testing treatments aimed at carcinoid syndrome, documented elevation of these markers may be mandatory. Some trials investigate whether reducing these marker levels correlates with symptom improvement or tumor shrinkage, making pre-treatment measurements essential for comparison.

Functional assessment tests evaluate how well your organs are working before you start experimental treatment. Blood tests checking kidney function, liver function, and blood cell counts ensure that your body can safely handle the investigational therapy. Many trials exclude patients with significant organ dysfunction because they face higher risks of treatment complications.

Documentation of symptoms provides important eligibility information, especially for trials focusing on carcinoid syndrome. Researchers may ask you to keep detailed diaries recording the frequency of diarrhea episodes, flushing events, or other symptoms for one to two weeks before enrollment. This creates an objective baseline against which symptom changes can be measured during treatment.

Some trials require documentation of prior treatments and their outcomes. This might include records showing that you’ve already tried standard therapies like somatostatin analogs, details about previous surgeries, or imaging that tracked tumor progression despite conventional treatment. Trials testing second-line or later-line therapies specifically seek patients whose disease has advanced despite earlier interventions.

Heart function testing may be required because carcinoid syndrome can affect heart valves, and some experimental treatments might influence cardiovascular function. An echocardiogram—an ultrasound of the heart—evaluates whether valve disease is present and how well your heart pumps^[22].

⚠️ Important

Participating in clinical trials requires more frequent testing and monitoring than standard care. While this means more doctor visits and diagnostic procedures, it also provides exceptionally close medical supervision. Trial participants often receive more detailed assessments of their disease and may gain access to promising treatments years before they become widely available. Discuss thoroughly with your medical team whether trial participation aligns with your goals and circumstances.

Prognosis and Survival Rate

Prognosis

The outlook for patients with gastrointestinal carcinoid tumors varies widely depending on several important factors. Location of the primary tumor significantly influences prognosis—carcinoid tumors in the appendix and rectum generally carry better outcomes than those originating in the small intestine or colon^[9]^[27].

Tumor size at diagnosis matters considerably. Carcinoid tumors smaller than one centimeter rarely show evidence of malignant behavior and have excellent prognosis. Those measuring between one and two centimeters show variable behavior, with some remaining benign and others showing aggressive characteristics. Tumors larger than two centimeters are almost always invasive or have already spread at the time of discovery^[9].

Whether the tumor has spread to other organs represents perhaps the most critical prognostic factor. Patients whose tumors remain confined to their original location have substantially better outcomes than those with distant metastases, particularly liver involvement^[27]. However, even patients with metastatic carcinoid disease often survive for years because these tumors typically grow slowly.

The presence or absence of carcinoid syndrome also influences prognosis. When carcinoid syndrome develops, it usually indicates that tumors have spread to the liver, which generally means more advanced disease. Additionally, longstanding carcinoid syndrome can lead to heart valve damage, which may complicate treatment and affect overall health^[6]^[22].

Importantly, carcinoid tumors generally carry better prognosis than adenocarcinomas, the more common type of cancer arising in the digestive tract^[9]^[27]. The slow-growing nature of most carcinoids means that even advanced disease may remain stable for extended periods, and various treatment options exist to control symptoms and tumor growth.

Survival Rate

Overall survival statistics for gastrointestinal carcinoid tumors are relatively encouraging compared to many other cancers. Analysis of nearly 14,000 carcinoid tumor cases revealed that 67 percent of patients survived at least five years regardless of where their tumor originated^[2]. This represents an average across all stages and locations, meaning many patients—particularly those diagnosed early—live much longer.

Survival rates differ substantially based on the extent of disease at diagnosis. Patients whose tumors are localized and completely removed through surgery often achieve cure, with survival rates approaching those of the general population. When tumors have spread to regional lymph nodes but not to distant organs, five-year survival remains reasonably favorable, though lower than for localized disease^[27].

Even patients with metastatic disease—where cancer has spread to the liver or other distant sites—can survive for years. The five-year survival rate for metastatic carcinoid disease, while lower than for localized tumors, still exceeds that of many other metastatic cancers due to the slow-growing nature of these tumors^[27].

Location-specific survival data shows that appendiceal carcinoid tumors have the best outcomes, with excellent long-term survival when removed surgically. Rectal carcinoids also carry favorable prognosis, particularly for smaller tumors. Small intestinal carcinoids present more challenges because they’re often discovered after spreading, yet many patients still achieve years of survival with appropriate treatment. Gastric carcinoids show variable outcomes depending on their subtype and association with other conditions^[27].

It’s worth noting that survival statistics represent averages from large groups of patients and cannot predict any individual’s outcome. Many factors influence how long someone lives with carcinoid disease, including overall health, response to treatment, and access to specialized care. Additionally, survival rates continue improving as new treatments become available and doctors gain more experience managing these rare tumors.

#1 Clinical Trials Search in Europe